MÂª Neus CarbÃ“ CarbÃ“

List of Publications by Year
in descending order

74 papers	3,050 citations	172457 29 h-index	161849 54 g-index
75 all docs	75 docs citations	75 times ranked	2708 citing authors

#	Article	IF	Citations
1	Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis. Cancers, 2021, 13, 3146.	3.7	29
2	Breast Mammographic Density: Stromal Implications on Breast Cancer Detection and Therapy. Journal of Clinical Medicine, 2020, 9, 776.	2.4	4
3	MiRNA:RBP Interplay as a Key Regulatory Element in Health and Disease. Proceedings of the Singapore National Academy of Science, 2020, 14, 123-143.	0.1	0
4	Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer. Cancer Letters, 2018, 424, 70-83.	7.2	35
5	Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. Breast Cancer Research, 2018, 20, 65.	5.0	7
6	Dual effects of Î²3 integrin subunit expression on human pancreatic cancer models. Cellular Oncology (Dordrecht), 2011, 34, 393-405.	4.4	4
7	Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Cellular Oncology (Dordrecht), 2011, 34, 511-521.	4.4	23
8	Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. Cancer Biology and Therapy, 2011, 11, 4-13.	3.4	8
9	Tumor promoting effects of CD95 signaling in chemoresistant cells. Molecular Cancer, 2010, 9, 161.	19.2	21
10	Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochemical Pharmacology, 2008, 76, 322-329.	4.4	40
11	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
12	Effects of interleukin-15 on lipid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 37-42.	2.4	50
13	Interleukin-15 decreases proteolysis in skeletal muscle: A direct effect. International Journal of Molecular Medicine, 2005, 16, 471.	4.0	24
14	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963.	4.0	2
15	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817.	4.0	4
16	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2
17	Adenovirus-Mediated Retinoblastoma 94 Gene Transfer Induces Human Pancreatic Tumor Regression in a Mouse Xenograft Model. Clinical Cancer Research, 2004, 10, 1454-1462.	7.0	11
18	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95

#	Article	IF	Citations
19	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
20	Mice lacking TNFÎ± receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death and Differentiation, 2003, 10, 997-1004.	11.2	54
21	Impaired voltage-gated K+channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
22	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
23	Increased tumour necrosis factorâ€Î± plasma levels during moderate-intensity exercise in COPD patients. European Respiratory Journal, 2003, 21, 789-794.	6.7	143
24	TNF-Î± is involved in activating DNA fragmentation in skeletal muscle. British Journal of Cancer, 2002, 86, 1012-1016.	6.4	71
25	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 2002, 1570, 33-37.	2.4	87
26	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2002, 188, 53-58.	7.2	1
27	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 17-24.	2.4	146
28	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters, 2001, 167, 33-38.	7.2	88
29	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. FEBS Letters, 2001, 505, 255-258.	2.8	29
30	Hepatic Transport of Gluconeogenic Substrates During Tumor Growth in the Rat. Cancer Investigation, 2001, 19, 248-255.	1.3	0
31	Reduced Muscle Redox Capacity after Endurance Training in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1114-1118.	5.6	158
32	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. Journal of Nutritional Biochemistry, 2000, 11, 431-435.	4.2	31
33	Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. British Journal of Cancer, 2000, 83, 526-531.	6.4	160
34	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
35	Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochimica Et Biophysica Acta - General Subjects, 2000, 1475, 5-9.	2.4	31
36	Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2000, 157, 99-103.	7.2	4

#	Article	IF	Citations
37	Does the mechanism responsible for TNF-mediated insulin resistance involve the proteasome?. Medical Hypotheses, 2000, 54, 565-569.	1.5	14
38	Tumour growth and nitrogen metabolism in the host (Review).. International Journal of Oncology, 1999, 14, 479.	3.3	3
39	Leptin and tumor growth in rats. , 1999, 81, 726-729.		41
40	Leptin administration to lactating rats is unable to induce changes in lipid metabolism in white adipose tissue or mammary gland. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1999, 84, 93-97.	1.1	4
41	Resveratrol, a Natural Product Present in Wine, Decreases Tumour Growth in a Rat Tumour Model. Biochemical and Biophysical Research Communications, 1999, 254, 739-743.	2.1	246
42	Prevention of cancer and cardiovascular diseases: A common strategy?. , 1998, 18, 139-148.		5
43	Leptin levels and gene expression during the perinatal phase in the rat. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 81, 95-100.	1.1	5
44	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Molecular and Cellular Endocrinology, 1998, 142, 183-189.	3.2	104
45	Tumour necrosis factor-Î± does not cross the rat placenta. Cancer Letters, 1998, 128, 101-104.	7.2	14
46	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
47	Was tumour necrosis factor-Î± responsible for the fetal malformations associated with thalidomide in the early 1960s?. Medical Hypotheses, 1998, 50, 313-318.	1.5	21
48	Short-term effects of leptin on lipid metabolism in the rat. FEBS Letters, 1998, 431, 371-374.	2.8	27
49	Tumor Growth Influences Skeletal Muscle Protein Turnover in the Pregnant Rat. Pediatric Research, 1998, 43, 250-255.	2.3	3
50	TNF and pregnancy: the paradigm of a complex interaction. Cytokine and Growth Factor Reviews, 1997, 8, 181-188.	7.2	46
51	Neutral amino acid transport in placental plasma membrane vesicles in the late pregnant rat: Evidence for a B0-like transport system. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1997, 71, 85-90.	1.1	13
52	Lipid metabolism in tumour-bearing mice:. Molecular and Cellular Endocrinology, 1997, 132, 93-99.	3.2	27
53	Comparative effects of Î²2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Letters, 1997, 115, 113-118.	7.2	44
54	The Increased Skeletal Muscle Protein Turnover of the Streptozotozin Diabetic Rat Is Associated with High Concentrations of Branched-Chain Amino Acids. Biochemical and Molecular Medicine, 1997, 61, 87-94.	1.4	44

#	Article	IF	Citations
55	Tumour growth and fetal uptake of amino acids in the pregnant rat. European Journal of Cancer, 1996, 32, 1413-1419.	2.8	1
56	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. Cancer Letters, 1996, 99, 7-14.	7.2	32
57	Anti-TNF Treatment Reverts Increased Muscle Ubiquitin Gene Expression in Tumour-Bearing Rats. Biochemical and Biophysical Research Communications, 1996, 221, 653-655.	2.1	69
58	Î±-Adrenergic receptors may contribute to the hypertriglyceridemia associated with tumour growth. Cancer Letters, 1996, 110, 213-216.	7.2	3
59	Tumour growth results in changes in placental amino acid transport in the rat: a tumour necrosis factor Î±-mediated effect. Biochemical Journal, 1996, 313, 77-82.	3.7	17
60	Administration of tumor necrosis factor-alpha results in a decreased placental transfer of amino acids in the rat.. Endocrinology, 1995, 136, 3579-3584.	2.8	27
61	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Letters, 1995, 91, 73-78.	7.2	24
62	Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Letters, 1995, 95, 33-38.	7.2	52
63	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. Cancer Letters, 1995, 97, 25-32.	7.2	21
64	The effects of tumour growth on circulating amino acids in the late pregnant rat. Cancer Letters, 1995, 88, 21-25.	7.2	1
65	Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway.. Journal of Clinical Investigation, 1995, 95, 2367-2372.	8.2	123
66	The effects of tumour necrosis factor-Î± on circulating amino acids in the pregnant rat. Cancer Letters, 1994, 79, 27-32.	7.2	3
67	Anti-Tumour Necrosis Factor-Î± Treatment Interferes with Changes in Lipid Metabolism in a Tumour Cachexia Model. Clinical Science, 1994, 87, 349-355.	4.3	70
68	Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.. Journal of Clinical Investigation, 1993, 92, 2783-2789.	8.2	264
69	Effects of tumour necrosis factor-? (cachectin) on glucose metabolism in the rat. Molecular and Cellular Biochemistry, 1992, 112, 53-9.	3.1	13
70	Metabolism of glucose in isolated intestinal cells from obese zucker rats. Nutrition Research, 1992, 12, 949-954.	2.9	0
71	Amino acid metabolism in several tissues of the obese Zucker rat as indicated by the tissue accumulation of Î±-amino[1-14C]isobutyrate. Molecular and Cellular Biochemistry, 1992, 110, 155-159.	3.1	2
72	Lipid metabolism in the obese Zucker rat. Disposal of an oral [14C]triolein load and lipoprotein lipase activity. Biochemical Journal, 1991, 274, 651-656.	3.7	19

#	Article	IF	Citations
73	Glucose handling by hepatocytes from obese Zucker rats. Bioscience Reports, 1991, 11, 285-292.	2.4	2
74	Plasma from pregnant rats has anti-tumoural activity. Oncology Reports, 0, , .	2.6	0